Century Therapeutics (IPSC) Net Income towards Common Stockholders (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$21.7 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 128.3% year-over-year to -$21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.2 million (down 365.81% YoY) and the FY2025 annual result came in at $39000.0, up 100.03% from the prior year.
• Net Income towards Common Stockholders fell to -$21.7 million in Q1 2026 per IPSC's latest filing, from -$9.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $76.6 million in Q1 2025 and bottomed at -$39.4 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$31.3 million (2023), against an average of -$24.4 million.
• The widest annual swing landed in 2025, when Net Income towards Common Stockholders jumped 372.82%; it then sank 128.3% in 2026.
• Tracing IPSC's Net Income towards Common Stockholders over 5 years: stood at -$31.7 million in 2022, then declined by 24.38% to -$39.4 million in 2023, then gained by 10.65% to -$35.2 million in 2024, then soared by 72.88% to -$9.5 million in 2025, then tumbled by 126.93% to -$21.7 million in 2026.
• Per Business Quant, the three latest IPSC Net Income towards Common Stockholders figures stand at -$21.7 million (Q1 2026), -$9.5 million (Q4 2025), and -$34.4 million (Q3 2025).

Peer Comparison